Citigroup
PCVX icon

Citigroup’s Vaxcyte PCVX Stock Holding History

Citigroup’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-29,900
Closed -$972K – 6259
2025
Q2 		$972K Buy
+29,900
New +$980K ﹤0.01% 3213
2025
Q1 		– Sell
-12,500
Closed -$1.02M – 5855
2024
Q4 		$1.02M Buy
+12,500
New +$1.24M ﹤0.01% 3350
2023
Q1 		– Sell
-6,200
Closed -$297K – 5767
2022
Q4 		$297K Hold
6,200
– – ﹤0.01% 3513
2022
Q3 		$149K Buy
+6,200
New +$157K ﹤0.01% 3904

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Citigroup's PCVX Position: Q3 2026 in Review

Citigroup reduced its Vaxcyte (PCVX) stake by 45% in Q3 2026, selling an estimated $5.31M and leaving 111,606 shares worth $6.35M. The position accounts for ﹤0.01% of the portfolio, ranked #1950.

Citigroup first reported a position in PCVX in Q3 2020 and has held it in 25 quarters since. The position peaked at $31M in Q4 2024. 171 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

  • Citigroup held 111,606 shares of Vaxcyte worth $6.35M as of Q3 2026.
  • Citigroup sold 91,067 Vaxcyte shares in Q3 2026, an estimated $5.31M.
  • Vaxcyte made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #1950 holding.
  • Citigroup first reported a position in Vaxcyte in Q3 2020 and has held it in 25 quarters since.
  • Citigroup's Vaxcyte position peaked at $31M in Q4 2024.
  • 171 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.